Affymax and Takeda aim to submit Hematide to the FDA in 2011

08/5/2010 | Bloomberg Businessweek

Affymax and Japanese partner Takeda Pharmaceutical plan to file for FDA approval of anemia treatment Hematide during the first half of next year. Affymax said it will pursue an application for the treatment of anemia in dialysis patients and continue evaluating the drug's nondialysis use.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA